CAMP and type 2 diabetes mellitus: Beyond that, the data presented here encourage the design of preclinical and clinical trials with macrolides, or other immunomodulatory agents targeting neutrophil LL-37 without increasing the risk of antibiotic resistance, in T2D (42).